Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) will convene its Annual General Meeting (AGM) on 25 June 2026 at 13:30, Meeting Room 601, Maple International Building Two, 450 Fenglin Road, Shanghai. Shareholders are set to vote on a total of 13 proposals spanning operational results, dividend plans, financial mandates and board composition.

Key ordinary resolutions include: • Approval of the 2025 Annual Report, Board Report, Final Accounts and the 2026 Financial Budget. • Endorsement of the 2025 Profit Distribution Plan and an interim dividend arrangement for 2026. • Re-appointment of the accounting firm, approval of external guarantees for 2026 and adoption of a new remuneration management system for directors and senior management.

Special resolutions focus on funding flexibility: • Authorization to issue debt-financing products. • Application for centralized registration of multiple new debt-financing instruments. • Renewal of the general mandate for future capital operations.

Board renewal will be handled through cumulative voting, with shareholders electing both non-independent and independent directors for the ninth board session.

Logistics and voting: • The record date for H-shareholders is 18 June 2026; share transfers must be lodged with Tricor Investor Services by 16:30 that day. • Proxy forms and related authorizations are due to Tricor at least 24 hours before the meeting. • All resolutions will be decided by poll, in accordance with Hong Kong Listing Rule 13.39(4).

The AGM is expected to last no more than half a day; participants will bear their own travel and accommodation expenses.